State of the art in pediatric nanomedicines
Drug Delivery and Translational Research · 2024
DOI: 10.1007/s13346-024-01532-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Saba Abedin und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, B3H 4R2, Canada. Hauptthemen laut MEDLINE: Nanomedicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 224 Literaturangaben. Gefördert von: Faculty of Health, Dalhousie University, College of Pharmacy, Dalhousie University.
Abstract (Originalsprache)
In recent years, the continuous development of innovative nanopharmaceuticals is expanding their biomedical and clinical applications. Nanomedicines are being revolutionized to circumvent the limitations of unbound therapeutic agents as well as overcome barriers posed by biological interfaces at the cellular, organ, system, and microenvironment levels. In many ways, the use of nanoconfigured delivery systems has eased challenges associated with patient differences, and in our opinion, this forms the foundation for their potential usefulness in developing innovative medicines and diagnostics for special patient populations. Here, we present a comprehensive review of nanomedicines specifically designed and evaluated for disease management in the pediatric population. Typically, the pediatric population has distinguishing needs relative to those of adults majorly because of their constantly growing bodies and age-related physiological changes, which often need specialized drug formulation interventions to provide desirable therapeutic effects and outcomes. Besides, child-centric drug carriers have unique delivery routes, dosing flexibility, organoleptic properties (e.g., taste, flavor), and caregiver requirements that are often not met by traditional formulations and can impact adherence to therapy. Engineering pediatric medicines as nanoconfigured structures can potentially resolve these limitations stemming from traditional drug carriers because of their unique capabilities. Consequently, researchers from different specialties relentlessly and creatively investigate the usefulness of nanomedicines for pediatric disease management as extensively captured in this compilation. Some examples of nanomedicines covered include nanoparticles, liposomes, and nanomicelles for cancer; solid lipid and lipid-based nanostructured carriers for hypertension; self-nanoemulsifying lipid-based systems and niosomes for infections; and nanocapsules for asthma pharmacotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
- College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, B3H 4R2, Canada. oadeleke@dal.ca.
ORCID-Profile: Oluwatoyin A Adeleke
Förderung
- Faculty of Health, Dalhousie University
- College of Pharmacy, Dalhousie University
Zitieren
APA
Abedin, S., & Adeleke, O. A. (2024). State of the art in pediatric nanomedicines. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01532-x
Vancouver
Abedin S, Adeleke OA. State of the art in pediatric nanomedicines. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01532-x
BibTeX
@article{Abedin2024,
author = {Abedin, Saba and Adeleke, Oluwatoyin A},
title = {State of the art in pediatric nanomedicines},
journal = {Drug Delivery and Translational Research},
year = {2024},
doi = {10.1007/s13346-024-01532-x}
}
EUVIMED